Piper Jaffray Companies restated their buy rating on shares of Titan Medical (NASDAQ:TMDI) in a research report report published on Monday morning, Stock Target Advisor reports. The firm currently has a $2.50 price objective on the stock.
A number of other brokerages have also weighed in on TMDI. ValuEngine upgraded Titan Medical from a hold rating to a buy rating in a research note on Thursday, August 1st. Maxim Group lowered Titan Medical from a buy rating to a hold rating in a research note on Wednesday, October 16th. Finally, Zacks Investment Research lowered Titan Medical from a buy rating to a hold rating in a research note on Saturday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $4.38.
NASDAQ TMDI traded up $0.03 during trading on Monday, reaching $0.61. The company’s stock had a trading volume of 1,029,418 shares, compared to its average volume of 391,651. The stock has a market capitalization of $14.96 million, a PE ratio of -0.42 and a beta of 4.61. The firm has a fifty day moving average of $0.68 and a 200 day moving average of $1.88. Titan Medical has a one year low of $0.38 and a one year high of $4.65.
About Titan Medical
Titan Medical Inc, a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures.
Featured Article: Hang Seng Index (HSI)
Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.